ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

RDHL vs ENLV // RSI-14 & 200D SMA MOMENTUM

Redhill Biopharma Ltd. (NASDAQ) VS. Enlivex Ltd. (NASDAQ) • 15-METRIC TALLY: RDHL 0 — ENLV 2
▲ RSI-14 & 200D SMA MOMENTUM LEADER: ENLV
rsi-technicals
65.3
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (RDHL VS. ENLV) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC RDHL ENLV SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) — -0.60% — TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield — — — TIE /fcf-yield <GO>
Operating Margin — — — TIE /operating-margins <GO>
Net Profit Margin — — — TIE /net-margins <GO>
Revenue Growth (YoY) — — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — — — TIE /balance-sheet <GO>
Piotroski F-Score Quality — 3/9 — TIE /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum ACTIVE 33.9 65.3 -31.47 ENLV /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $3.7M $3.9M -$188.7K ENLV /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR RDHL REV ENLV REV RDHL GROSS % ENLV GROSS % RDHL FCF ENLV FCF
FY 2025 — $0 — — — -$10.5M
FY 2024 — $0 — — — -$13.1M
FY 2023 — $0 — — — -$23.5M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
RDHL // BETA —
ENLV // BETA —